Enoximone

Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3].

Product Specifications

CAS Number

[77671-31-9]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/enoximone.html

Purity

99.91

Solubility

DMSO : 8.33 mg/mL (ultrasonic)

Smiles

O=C1NC(C)=C(N1)C(C2=CC=C(C=C2)SC)=O

Molecular Formula

C12H12N2O2S

Molecular Weight

248.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3 (2) :e94888.|[2]R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33.|[3]M B Vroom, et al. Effect of Phosphodiesterase Inhibitors on Human Arteries in Vitro. Br J Anaesth. 1996 Jan;76 (1) :122-9.